Acute cholecystitis is a common surgical condition that often requires emergency care, with approximately 12,000 hospitalizations each year in the Netherlands and Belgium. For patients who have experienced symptoms for more than 5 days, the optimal treatment strategy remains unclear: surgery performed during the initial hospital admission, or conservative treatment without surgery? Currently, hospitals use different treatment approaches, resulting in variation in care that may lead to differences in outcomes, more complications, and longer hospital stays.
This study aims to determine whether early surgery during the initial hospital admission leads to better outcomes than starting with a non-operative approach. The study will be conducted in multiple hospitals across the Netherlands and Belgium. A total of 324 patients will be randomly assigned to one of two treatment groups: early surgery or initial conservative management without immediate surgery. All patients will be followed for 1 year.
The study aims to improve the treatment of acute cholecystitis. Key outcome measures include complications, quality of life, and healthcare costs. The results may contribute to more effective and standardised care, reduce unnecessary complications, and shorten hospital stays.
| Title | Same admission cholecystectomy vs initial conservative management in patients with acute cholecystitis and > 5 days of symptoms: a multicentre randomised controlled trial (BRAVE trial) |
| Participants (P) | Patients with Tokyo criteria-defined acute calculous cholecystitis and symptom onset 6-10 days before day of diagnosis |
| Intervention (I) | Initial conservative management followed by the local treatment protocol |
| Control (C) | Same-admission Laparoscopic cholecystectomy (LC), defined as LC within < 72 hours of moment of diagnosis |
| Outcome (O) | Proportion of patients experiencing at least one disease-related adverse event of grade ≥ 3, as defined by the Common Terminology Criteria for Adverse Events (CTCAE, version 6.0), within 12 months after study inclusion |
| Trial Design | |
| Sample Size | 324 patients (183 NL, 141 BE) |
| Trial duration | Study duration (FPI to CSR) 36 months |
| Budget | 440,000 € for Belgian Coordinating Centre |
| Sponsor | Radboud University Medical Center |
| Chief Investigator | Dr P R de Reuver |
| External Partners | BCC Jessa Ziekenhuis, National Coordinating Investigator: Dr. B.M.G. Appeltans |
| Number of participating sites | 19 sites (11 NL, 8 BE) |
Clinicaltrials.gov:
Webpage: